374 related articles for article (PubMed ID: 22777932)
1. Identification of novel glycolipid ligands activating a sulfatide-reactive, CD1d-restricted, type II natural killer T lymphocyte.
Rhost S; Löfbom L; Rynmark BM; Pei B; Månsson JE; Teneberg S; Blomqvist M; Cardell SL
Eur J Immunol; 2012 Nov; 42(11):2851-60. PubMed ID: 22777932
[TBL] [Abstract][Full Text] [Related]
2. Multiple tissue-specific isoforms of sulfatide activate CD1d-restricted type II NKT cells.
Blomqvist M; Rhost S; Teneberg S; Löfbom L; Osterbye T; Brigl M; Månsson JE; Cardell SL
Eur J Immunol; 2009 Jul; 39(7):1726-35. PubMed ID: 19582739
[TBL] [Abstract][Full Text] [Related]
3. Involvement of secretory and endosomal compartments in presentation of an exogenous self-glycolipid to type II NKT cells.
Roy KC; Maricic I; Khurana A; Smith TR; Halder RC; Kumar V
J Immunol; 2008 Mar; 180(5):2942-50. PubMed ID: 18292516
[TBL] [Abstract][Full Text] [Related]
4. [Sulfatide-loaded CD1d tetramer to detect typeII NKT cells in mice].
Zhang GQ; Nie HX; Yang J; Yu HY
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Jul; 28(7):696-8. PubMed ID: 22768857
[TBL] [Abstract][Full Text] [Related]
5. Atypical natural killer T-cell receptor recognition of CD1d-lipid antigens.
Le Nours J; Praveena T; Pellicci DG; Gherardin NA; Ross FJ; Lim RT; Besra GS; Keshipeddy S; Richardson SK; Howell AR; Gras S; Godfrey DI; Rossjohn J; Uldrich AP
Nat Commun; 2016 Feb; 7():10570. PubMed ID: 26875526
[TBL] [Abstract][Full Text] [Related]
6. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide.
Jahng A; Maricic I; Aguilera C; Cardell S; Halder RC; Kumar V
J Exp Med; 2004 Apr; 199(7):947-57. PubMed ID: 15051763
[TBL] [Abstract][Full Text] [Related]
7. Defining a novel subset of CD1d-dependent type II natural killer T cells using natural killer cell-associated markers.
Singh AK; Rhost S; Löfbom L; Cardell SL
Scand J Immunol; 2019 Sep; 90(3):e12794. PubMed ID: 31141185
[TBL] [Abstract][Full Text] [Related]
8. Autoreactivity to Sulfatide by Human Invariant NKT Cells.
Stax AM; Tuengel J; Girardi E; Kitano N; Allan LL; Liu V; Zheng D; Panenka WJ; Guillaume J; Wong CH; van Calenbergh S; Zajonc DM; van den Elzen P
J Immunol; 2017 Jul; 199(1):97-106. PubMed ID: 28526683
[TBL] [Abstract][Full Text] [Related]
9. Identification of canine natural CD3-positive T cells expressing an invariant T-cell receptor alpha chain.
Yasuda N; Masuda K; Tsukui T; Teng A; Ishii Y
Vet Immunol Immunopathol; 2009 Dec; 132(2-4):224-31. PubMed ID: 19748683
[TBL] [Abstract][Full Text] [Related]
10. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
[TBL] [Abstract][Full Text] [Related]
11. Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells.
Sriram V; Du W; Gervay-Hague J; Brutkiewicz RR
Eur J Immunol; 2005 Jun; 35(6):1692-701. PubMed ID: 15915536
[TBL] [Abstract][Full Text] [Related]
12. NKT and tolerance.
Diana J; Beaudoin L; Gautron AS; Lehuen A
Methods Mol Biol; 2011; 677():193-206. PubMed ID: 20941612
[TBL] [Abstract][Full Text] [Related]
13. Sulfatide inhibits α-galactosylceramide presentation by dendritic cells.
Kanamori M; Tasumi Y; Iyoda T; Ushida M; Inaba K
Int Immunol; 2012 Feb; 24(2):129-36. PubMed ID: 22247226
[TBL] [Abstract][Full Text] [Related]
14. Distinct CD1d docking strategies exhibited by diverse Type II NKT cell receptors.
Almeida CF; Sundararaj S; Le Nours J; Praveena T; Cao B; Burugupalli S; Smith DGM; Patel O; Brigl M; Pellicci DG; Williams SJ; Uldrich AP; Godfrey DI; Rossjohn J
Nat Commun; 2019 Nov; 10(1):5242. PubMed ID: 31748533
[TBL] [Abstract][Full Text] [Related]
15. NKT TCR recognition of CD1d-α-C-galactosylceramide.
Patel O; Cameron G; Pellicci DG; Liu Z; Byun HS; Beddoe T; McCluskey J; Franck RW; Castaño AR; Harrak Y; Llebaria A; Bittman R; Porcelli SA; Godfrey DI; Rossjohn J
J Immunol; 2011 Nov; 187(9):4705-13. PubMed ID: 21964029
[TBL] [Abstract][Full Text] [Related]
16. Type II NKT cells: a distinct CD1d-restricted immune regulatory NKT cell subset.
Dasgupta S; Kumar V
Immunogenetics; 2016 Aug; 68(8):665-76. PubMed ID: 27405300
[TBL] [Abstract][Full Text] [Related]
17. CD4(+) type II NKT cells mediate ICOS and programmed death-1-dependent regulation of type 1 diabetes.
Kadri N; Korpos E; Gupta S; Briet C; Löfbom L; Yagita H; Lehuen A; Boitard C; Holmberg D; Sorokin L; Cardell SL
J Immunol; 2012 Apr; 188(7):3138-49. PubMed ID: 22371394
[TBL] [Abstract][Full Text] [Related]
18. Crystal structures of bovine CD1d reveal altered αGalCer presentation and a restricted A' pocket unable to bind long-chain glycolipids.
Wang J; Guillaume J; Pauwels N; Van Calenbergh S; Van Rhijn I; Zajonc DM
PLoS One; 2012; 7(10):e47989. PubMed ID: 23110152
[TBL] [Abstract][Full Text] [Related]
19. Sulfatide administration leads to inhibition of HIV-1 replication and enhanced hematopoeisis.
Sundell IB; Halder R; Zhang M; Maricic I; Koka PS; Kumar V
J Stem Cells; 2010; 5(1):33-42. PubMed ID: 20861926
[TBL] [Abstract][Full Text] [Related]
20. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
Wu L; Gabriel CL; Parekh VV; Van Kaer L
Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
